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Background: Stanozolol is a synthetic derivative of dihydrotestosterone (DHT), and one of the frequently detected
anabolic steroids in doping analysis. The current work describes the development and validation of the
stability-indicating TLC-densitometric method for sensitive and specific estimation of stanozolol even its
degradation product being there. Precoated silica gel TLC aluminium plates were utilized as the stationary phase
and the eluent comprised of petroleum ether: acetone (6:4, v/v). Densitometric analysis of stanozolol was achieved
at λmax 750 nm in the absorbance mode after staining with phosphomolybdic acid (PMA). Stress degradation of
stanozolol was carried out under various reaction conditions including acid, base and neutral hydrolysis, wet and
dry heating treatment, oxidation, and photo-degradation. Resulted stress samples and pharmaceutical products
were analyzed with the developed TLC method.
Results: This system showed a compact spot for stanozolol at Rf value of 0.46 ± 0.02. The data of linear regression
analysis indicated a good linear relationship over the range of 200–1200 ng/spot concentrations. The method was
validated for robustness, precision and recovery. The LOD and LOQ were 1.6 and 5.1 ng/spot, respectively. Under
various stressed conditions, stanozolol showed degradation only under acidic hydrolysis. Peak of a degraded
product was well resolved from the stanazolol with reasonably different Rf value and identified as 17,
17-dimethyl-l8-nor-5α-androst-13(14)-eno [3,2c] pyrazole through 1D- and 2D-NMR spectroscopic techniques and
ESI-QqTOF-MS/MS analysis.
Conclusion: Result reflected that the stanozolol is majorly affected by the acidic condition. Statistical analysis
indicated the application of the developed stability-indicating TLC-densitometric method for routine analysis of
stanozolol in the presence of its degradation product.
Keywords: Stanozolol; TLC-densitometry; Stress degradationStanozolol (5α-androstane-17α-methyl-17β-ol [3,2-c] pyr-
azole), a heterocyclic anabolic androgenic steroid was first
synthesized by Clinton in 1959 [1]. It differs in structure
with endogenous steroid hormones and most commonly
used exogenous anabolic steroids [2]. Despite the restric-
tion by the International Olympic Committee (IOC) since
1974, stanozolol is one of the most frequently misused
synthetic anabolic steroids in sport. Several authors
reported it’s used in the treatment of osteoporosis and de-
ficiency in protein synthesis [3-5]. It is also used in* Correspondence: musharraf1977@yahoo.com
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distribution, and reproduction in any mediumveterinary medicine to boost appetite, to weight gain, and
for the treatment of certain types of anemia [6,7].
In order to develop stability indicating methods, stress
degradation study is a powerful tool used routinely in
pharmaceutical development that lead to a quality stabil-
ity data and to recognize the degradation pathways of
the active drug ingredient and its products. These deg-
radation studies are employed for monitoring the drug
stability which provides evidence that in what manner
drug quality varies with passage of time by the conse-
quence of different environmental factor including tem-
perature, light, humidity, etc. and effect of stomach and
intestine pH. Various strategies and principles are pro-
vided by International Conference on Harmonizationntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Rf values and peak widths of stanozolol in
different mobile phases
S. No. Compositions (v/v) Proportions Rf Peak
widths (cm)
1 Petroleum ether-acetone 8:2 0.24 0.07
2 petroleum ether-acetone 7.5:2.5 0.29 0.09
3 Petroleum ether-acetone 6:4 0.46 0.06
4 Hexane-ethyl acetate 8:2 0.05 0.06
5 Chloroform-methanol 9:1 0.17 0.09
6 Dichloromethane-methanol 9.2:0.8 0.13 0.09
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studies [8-10].
Different analytical techniques such as gas chromatog-
raphy–mass spectrometry (GC-MS), high performance
liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS), high throughput ultra performance liquid chro
matography-tandem mass spectrometry (UHPLC-ESI -MS/
MS) have been described for the analysis of stanozolol in
variety of biological samples [11-14]. However, there is no
report for the development of stability-indicating TLC-
densitometric method for the quantification of stanozolol
in the presence of its degraded products so far. Currently,
TLC-densitometric method getting considerable attention
on account of its various benefits including simultaneous
running number of samples, utilizing little amount of elu-
ent in contrast to HPLC, reduced cost and analysis time,
mobile phase of extreme pH and direct application of vari-
ous type of samples (dirty, turbid or suspensions) can also
be employed [15].
In continuation of our studies on the determination of
organic compounds of biological interest and pharma-
ceutical importance [16-19], and taking ICH guidelines
Q1A in consideration, present study describes a simple
stability-indicating TLC densitometric method for the
quantification of stanozolol in presence of its degraded
products formed under the applied stress conditions.
Experimental
Standards and chemicals
Standard stanozolol was purchased from Sigma Aldrich
(USA). Stanozolol® tablets (containing 5 mg stanozolol/
tablet (S1) and 10 mg stanozolol/tablet (S2) manufac-
tured by LA Pharma S.r.I) were procured from the local
pharmacies of Karachi, Pakistan. Aluminum sheets pre-
coated with silica gel (60F-254, 20 cm × 20 cm) were
purchased from the Merck (Germany). Hydrochloric
acid (HCl) and hydrogen peroxide (H2O2, 35% v/v) were
purchased from the Fisher Scientific (UK) while sodium
hydroxide was procured from the BioM Laboratories
(Cerritos, USA). Deionized water was acquired from
Millipore Milli Q Plus System (Bedford, USA). All add-
itional analytical grade reagents and chemicals were pro-
cured from Merck (Germany).
Chromatographic state and instrumentation
A CAMAG automatic TLC sampler (Linomat 5) was used
for the spotting of all samples and standards, which were
spotted in the form of bands of width 6 mm with a
CAMAG 100 μL syringe on pre-coated silica gel TLC
aluminum sheets. CAMAG Reprostar 3 was used for the
video densitometry of the chromatoplate, and the inte-
grated software of WinCATS was used for the analysis.
Sample was applied at the constant rate of 0.1 μL/s and
9.1 mm space between the two bands was maintained. Theeluent composed of petroleum ether and acetone (6:4, v/v).
20 cm × 10 cm CAMAG twin trough glass chamber was
used for linear ascending development of TLC plate under
unsaturated condition and 10 mL of organic solvent was
consumed per run. The TLC plate was developed up to a
distance of 80 mm. Chromatographic process was carried
out at room temperature (25 ± 2°C) with relative humidity
of 42 ± 5%. The developed TLC plate was dried with the
help of air dryer for 5 min and subjected to the staining
process using CAMAG Chromatogram Immersion Device.
Phosphomolybdic acid (PMA) was used to visualize the an-
alyte. The analyte complexed with PMA was then heated
with CAMAG TLC Plate Heater 3 at 120–125°C for 3–4
minutes. CAMAG TLC Scanner 3 was used for scanning
at λmax 750 nm and operates in reflection absorbance
mode by winCATS software. Each sample and standard
level was spotted in triplicate, and during scanning baseline
correction was employed. Evaluation was accomplished via
peak areas using linear regression.Calibration curve of stanozolol
Stock solution of stanozolol (1 mg mL-1) was prepared in
methanol. The stock solution was further diluted to obtain
a series of working standards over the range of 200–1200
ng spot-1 for calibration curve. Prepared solutions were
stored at 4°C until use. Each working standard was spotted
in triplicate, total 18 tracks were spotted on each TLC plate.
The spot volume of each standard level was 5 μL. The spot-
ted plate was developed as mentioned in previous section.
This practice was repeated six times to get an average
standard calibration curve. Linear least- square regression
was performed on the data of peak areas plotted versus the
corresponding concentrations.Validation of method
The method validation was done as described by the ICH
guidelines. The method sensitivity was estimated with re-
spect to limit of detection (LOD), limit of quantification
(LOQ) and correlation coefficient. Working solutions
containing 200–1200 ng of stanozolol were spotted on
TLC aluminum sheet. In order to evaluate LOD and LOQ,
Figure 1 HPTLC chromatogram of standard stanozolol (800 ng/
spot) and acid treated (1N HCl, reflux for 2 hr at 80°C; 1000 ng/
spot) after staining with phosphomolybdic acid (PMA),
stanozolol peak has Rf = 0.46 ± 0.02 (a) and degradant has Rf =
0.55 (b): mobile phase; petroleum ether: acetone (6:4, v/v).
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following equation: LOD = 3.3 δ/S, LOQ = 10 δ /S where,
S = the slope of the calibration curve, δ = the residual
standard deviation of regression line or the Y-intercept of
regression line. The LOD and LOQ were estimated as 3
and 10 times of the noise level, correspondingly. Moreover,
both were tentatively determined by diluting the familiar
concentration of stanozolol standard till the mean instru-
mental responses were nearly three and ten times of
the standard deviation of the responses for six manifold
analyses.
The Intra- and inter-day variation for the estimation
of stanozolol was evaluated for method precision. It was
achieved by using three different concentration levels of
300, 500 and 700 ng spot-1. Repeated analyses were car-
ried out in a same day for intra-day analysis while the
same practice was repeated next day for inter-day ana-
lysis. Intra- and inter-day analyses were performed to
check the repeatability and reproducibility of the method,Table 2 Precision and accuracy for quality control standard o
A
Intra-day I
Conc. Found* R.S.D. Accuracy Found*
(ng) (ng) % (%) (ng)
300 303.56 ± 5.00 1.65 98.81 306.63± 5.52
500 503.33 ± 1.06 0.21 99.33 504.49± 3.38
700 705.80 ± 1.50 0.21 99.17 703.85± 1.14
*Values are mean of n = 3.respectively and results were statistically evaluated in
terms of % R.S.D. In order to check the robustness, follow-
ing parameters were intentionally changed within the
range of ± 5% at 300, 500 and 700 ng/ spot concentration
level; mobile phase composition, different types of TLC
plates e.g., silica-gel glass plates and aluminum sheets of
other supplier (Macherey-Nagels, Germany), time from
spotting to chromatography, time from chromatography
to staining, time for staining and time from staining to
scanning. The accuracy of the method was assessed by
performing recovery study of pre-analyzed samples, spiked
with extra 50, 100 and 150% standard stanozolol. The ana-
lysis of spiked samples was repeated six times.
Preparation and analysis of pharmaceutical products
To estimate the stanazolol content in pharmaceutical pro-
ducts, the tablets (label claim: 5 mg/tablet, 10 mg/tablet)
were crushed and amount equivalent to one tablet was
extracted in 2 mL methanol. To confirm the complete
extraction of the stanazolol, it was shaken at 40°C for 20
minutes in a thermomixer (Eppendorf® Thermomixer
Comfort, UK) at 300 rpm. The resulting solution was
filtered with glass syringe with disposable micropore fil-
ter tips (13 mm × 0.45 μm Teflon filter) and the filtrate
was used for the drug content analysis. From the filtrate,
5 μL was spotted onto the plate and then development,
staining and scanning were done as previously described.
This was repeated in triplicate.
Preparation of forced degradation products
Stress degradation studies of stanozolol were performed
using parallel synthesizer (Smart Start Synthesizer, Chem
Speed Ltd., Switzerland). Stock solution (1 mg mL-1) was
used for forced degradation. After the completion of reac-
tion, all the resulting solutions were preserved at −20°C
prior to analysis. Average peak areas of active components
were analyzed after triplicate analysis. For acidic hydroly-
sis, 0.1N, 1N and 5N HCl were used, for alkaline hydroly-
sis, 0.1N, 1N and 5N NaOH were used while for neutral
hydrolysis Milli Q water was used. 3 mL of each concen-
tration of acidic and alkaline solutions and Milli Q water
were added into 3 mL (1 mg/mL) stock solutions of each.f stanazolol
nalyst 1 Analyst 2
nter-day
R.S.D. Accuracy Found* R.S.D. Accuracy
% (%) (ng) % (%)
1.80 97.79 300.62± 1.452 0.48 99.79
0.67 99.10 502.63± 0.78 0.15 99.47
0.16 99.45 703.04± 0.71 0.10 99.56
Table 3 Robustness testing (n = 6)
Standard
level



























300 303.7 ± 11.54 3.80 298.3 ± 1.54 0.51 311.29 ± 8.03 2.58 284.18 ± 6.81 2.39 300.63 ± 9.34 3.11 287.3 ± 10.06 3.5
500 505.01 ±12.44 2.46 500.7 ±13.58 2.71 498.51 ± 18.85 3.78 513.85 ± 6.91 1.34 516.18 ± 2.58 0.50 508.53 ± 12.96 2.54






















50 351.5 92.2 5.00
S1 100 468.7 95.2 5.99
150 585.9 94.6 1.76
Table 5 Summary of validation parameters
Parameter Data of standard stanazolol
(at λmax 750 nm)
Linearity range 200-1200 ng/spot
Correlation coefficient 0.9990 ± 0.0004
Limit of detection (LOD) 1.6 ng/spot
Limit of quantification (LOQ) 5.1 ng/spot
Y = mx + c Y = 5.841x + 1420.3
Slope ± SD 5.841 ± 0.755
Intercept ± SD 1420.3 ± 36.4
Intra-day analysis (n=3), 0.690
% R.S.D.




Musharraf et al. Chemistry Central Journal 2013, 7:142 Page 5 of 8
http://journal.chemistrycentral.com/content/7/1/142To study wet heating degradation, 3 mL (1 mg/mL) of
stock solution was used. Oxidation was carried out by
adding 3 mL of H2O2 (35% v/v and 5% v/v) in 3 mL stock
solution of each set. All the resultant solutions were
refluxed for two hours at 80°C in parallel synthesizer in
the dark, in order to prohibit the possible degradative ef-
fects of light. 2 μL (1000 ng/spot) of 0.1N, 1N and 5N HCl
treated solution, 0.1N, 1N and 5N NaOH treated solu-
tions, and neutral hydrolysis solution while 1 μL (1000 ng/
spot) of wet-heating degradation mixture and 2 μL (1000
ng/spot) from oxidation mixture solution were applied on
TLC plate in triplicate and densitogram were developed.
Dry heating degradation was conducted by taking stand-
ard stanozolol and heated in oven at 90°C for 6 hrs. Photo-
chemical degradation was conducted by taking standard
stanozolol and placed in direct sunlight for three days from
8 to 18 hrs at 30 ± 2°C. 1 mg of each treated standard was
dissolved in 2 mL of methanol and 2 μL (1000 ng/spot) of
each resultant solution was spotted on TLC plate in tripli-
cate for chromatographic analysis. For oxidation reaction
at room temperature, 3 mL stock solution of stanozolol
was added with 3 mL of H2O2 (35% v/v) and the resultant
solution was kept for 24 hours at room temperature. 2 μL
(1000 ng/spot) of treated solution was applied on TLC
plate in triplicate for chromatographic analysis.
Isolation and characterization of acid
degradation product
In order to isolate the acid degradation product in bulk
amount, 500 mg of stanozolol in methanol (1 mg/mL)
was refluxed in 1N HCl for 3 hours and monitored by
TLC analysis (petroleum ether: acetone; 6:4, v/v). At the
end of reaction, the mixture was neutralized with sodium
bicarbonate solution and extracted with dichloromethane.
The reaction mixture was loaded on to a silica gel column,
which on elution with hexane: ethyl acetate; 6.5:3.5, v/v
afforded purified degradation product (110 mg; 22% yield)
which was identified with the aid of 1D- and 2D-NMR
spectroscopic techniques and ESI-QqTOF-MS/MS analysis.
Results and discussion
Method optimization
For the development of chromatographic method, the
mobile phase composition was optimized with a view to
develop stability-indicating assay method. TLC sheet was
simultaneously spotted with standard stanozolol, pharma-
ceutical samples and degraded products and was developed
in different solvent systems. Various mobile phases were
tried to resolve stanozolol from its degraded products. Rf
values and peak widths of stanozolol in different mobile
phases are summarized in Table 1. Suitable separation with
best resolution was achieved with petroleum ether and
acetone (6:4, v/v). This system showed sharp and symmet-
rical peaks of stanozolol and its acid degradation productunder unsaturated condition with Rf value at 0.46 ± 0.02
and 0.55 ± 0.01 respectively, (Figure 1) with 1.5 resolu-
tion. Various derivatizing agents like ceric sulfate, vanillin,
phosphomolybdic acid (PMA) and ceric ammonium sul-
fate were tried. However, derivatization with phospho-
molybdic acid (PMA) gave significantly better result, the
spots are visible, sharper and more colourful as compared
to the plate sprayed with other derivatizing agents de-
scribed above.
The linear regression data for the calibration curves
(n = 6) showed a good linearity r = 0.9990 ± 0.0004,
(Slope = 5.841 ± 0.755, Intercept = 1420.3 ± 36.4) over
the concentration range of 200–1200 ng/spot with respect
to peak area. In residual linearity test of stanozolol, the
random pattern of residuals against respective standard
levels showed a linear model of standard calibration curves
Additional file 1: Figure S1).
Method validation
The repeatability and reproducibility were showed in terms
of percentage relative standard deviation (R.S.D. %) be-
tween two analyses and was found to be < 2% (Table 2).
Similarly, intra- and inter-day variation of stanozolol at
three different concentration levels 300, 500 and 700 ng/
spot was found to be < 2% in all the cases (Table 2).




% Recovery % Degradation Rf of degraded
products
Acidic hydrolysis a
0.1N HCl 88.28 11.72 0.49, 0.55
1N HCl 76.25 23.75 0.49, 0.55
5N HCl 45.07 54.93 0.49, 0.55
Basic hydrolysis a
0.1N NaOH 98.40 1.60 Not detected
1N NaOH 95.19 4.81 Not detected
5N NaOH 90.71 9.29 Not detected
Neutral hydrolysis a 98.65 1.35 Not detected
Wet heating a 99.59 0.41 Not detected
Dry heating 98.32 1.68 Not detected
Oxidation a
5%v/v H2O2 97.90 2.10 Not detected
35%v/v H2O2 99.59 0.41 Not detected
Oxidation at room temp 98.30 1.70 Not detected
Photostability-daylight 98.62 1.38 Not detected
aReflux in parallel synthesizer for two hours at 80°C.
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levels (300, 500 and 700 ng) was estimated for each par-
ameter for robustness analysis. Mean % R.S.D. was 2.4
for varying in mobile phase composition, 1.39 for the
use of different TLC plates, 2.27 for varying time from















Scheme 1 Proposed acid degradation pathway of stanozolol.chromatography to staining, and 1.77 for varying time for
staining and 2.1 for varying time from staining to scanning
(Table 3). RSD % is reasonably low (< 2.5%) for all parame-
ters which indicates the robustness of the developed
method. The LOD for standard stanozolol with signal/noise
ratio of 3:1 was found to be 1.6 ng per spot and LOQ with
signal/noise ratio 10:1 was found to be 5.1 ng/spot. This
showed the satisfactory sensitivity of the developed method.
The spectra were compared at peak start, peak apex and
peak end positions of the spot, to check the peak purity of
stanozolol. Excellent correlation, r2 (start to middle) =
0.9996 and r2 (middle to end) = 0.9998 was observed by
comparing the spectra of standard and corresponding peak
in pharmaceutical samples. Spiking with 50, 100 and 150%
of additional standard stanozolol afforded recovery of 92.2–
95.2% as showed in Table 4. This practice was repeated six
times. Summary of all validation parameters is highlighted
in Table 5.Analysis of commercial dosage form
In chromatogram of tablet’s extracted samples, a single
spot (Rf value of 0.46 ± 0.02) was observed correspond-
ing to stanazolol. No interference from the excipients
and binders commonly present in the marketed tablet
formulation was observed. Two different dose strengths,
5 and 10 mg were analysed through developed method
and it showed drug content of 5.198 ± 0.16 mg and
10.126 ± 0.25 mg, respectively. The mean percent recov-
ery of the proposed method is 103.96 for S1 and 101.26
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maceutical products.Stability-indicating property
Stanazolol was subjected to various stress degradation
conditions. The chromatogram of stanozolol treated with
different strength of acid showed well-separated peak
of stanozolol as well as one additional peak of degradant
(Rf = 0.55) (Figure 1). Stanazolol showed 11.7%, 23.7% and
54.9% degradation under 0.1N HCl, 1N HCl and 5N HCl
conditions, respectively. Very low degradation was also
observed after exposing the stanozolol to stressed condi-
tions of base, and neutral hydrolysis, wet and dry heating,
sunlight and oxidation. However, peaks of degraded prod-
ucts were not observed. Results of the stress degradation
studies are summarized in Table 6. Acid degradation prod-
uct was purified and characterized through various spectro-
scopic methods as 17, 17-dimethyl-l8-nor-5α-androst-13
(14)-eno [3,2c] pyrazole which was earlier reported as a
synthetic derivative of stanozolol [20]. The HRESI-MS (pos-
itive mode) showed peak [M+H]+ peak at m/z 311.2452
corresponding to C21H31N2 (calc. 311.2481), 18 amu less
than stanozolol, indicating a dehydrated product. The ESI-
MS/MS analysis of m/z 311 [M+H]+ showed base peak at
m/z 81, corresponding to pyrazole ring (Additional file 1:
Scheme S1). The product ion at m/z 95 is suggested to
derive from the same protonated species as m/z 81 by a
rearrangement of the bonds. Fragment due to retro Diel-
Alder cleavage was observed at m/z 189 from fragments
m/z 311. The CID-MS/MS spectra and proposed mechan-
istic fragmentation pathway are shown in Additional file 1:
Figure S2 and Additional file 1: Scheme S1, respectively
and the characteristic MS/MS fragments are summarized
in Additional file 1: Table S2. Proposed mechanism for the
acid degradation of stanozolol is shown in Scheme 1. 13C-
NMR and 1H-NMR data of a degraded product is pro-
vided in Additional file 1: Figure S3 and Additional file 1:
Table S1.Conclusion
A new stability-indicating TLC method combined with
densitometry has been developed and validated for the
identification and quantification of stanozolol in its phar-
maceutical dosage form. Satisfactory precision and accur-
acy, minimum cost, and quicker analysis are the core
features of this method. The ICH guideline was followed
for method validation. Reproducibilty and specificity of
method was determined by statistical analysis. Moreover,
this study demonstrates the degradation susceptibility of
stanozolol to different stress conditions and thus helps
in determining the changes in chemical and physical
properties of the stanozolol with the passage of time.
Current study may be expanded to degradation kineticsof stanozolol and for its assessment in urine, plasma,
serum and other biological fluids.
Additional file
Additional file 1: Figure S1. Standard calibration curve (A) and its
residual linearity test (B). Figure S2 CID-MS/MS spectra of acid-degradation
product of stanozolol at the collision energy of 45 ev. Figure S3 13C-NMR
and 1H-NMR (400 MHz, CDCl3) spectra of acid degradation product of
stanozolol Table S1 13C-NMR and 1H-NMR (400 MHz, CDCl3) chemical
shifts of acid degradation product of stanozolol (δ in ppm). Table S2
Elemental composition of daughter ions of acid degradation product of
stanozolol (m/z 311). Scheme S1 Proposed CID-MS/MS fragmentation
pathway of acid-degradation product of stanozolol.
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